Methods for reducing global chronic inflammation and the presence of melanoma
This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.
1. A method for treating a mammal having stage IV melanoma, said method comprising:
(a) administering to said mammal an anti-chronic inflammation treatment,
(b) detecting, in a blood sample obtained from said mammal, a reduction in IL-4, IL-5, IL-10, and IL-13 level following said step (a), wherein said reduction is indicative of reduced global chronic inflammation, and
(c) after detecting said reduced global chronic inflammation, administering to said mammal a cancer treatment agent under conditions wherein the presence of said melanoma is reduced, wherein said cancer treatment agent is paclitaxel, carboplatin, bevacizumab, anti-CTLA-4, a MART-1 cancer vaccine, a gp 100 cancer vaccine, a survivin cancer vaccine, or a tyrosinase cancer vaccine.
2. The method of claim 1 , wherein said mammal is a human.
3. The method of claim 1 , wherein said anti-chronic inflammation treatment comprises chemotherapy, radiation, an anti-IL-4 agent, an anti-IL-13 agent, or a steroid treatment.
4. The method of claim 1 , wherein said cancer treatment agent is a cancer vaccine.
5. The method of claim 1 , wherein said cancer vaccine is a Melan-A (MART-1), gp100, or survivin cancer vaccine.
6. The method of claim 1 , wherein the period of time between the last administration of said anti-chronic inflammation treatment and the first administration of said cancer treatment agent is between two weeks and six months.